by David Wallace Key Points Rusfertide achieved clinical response in 77% of patients compared to 33% with placebo in the Phase 3 VERIFY trial The drug significantly reduced the number of blood draws needed each year and decreased PV-related symptoms Rusfertide maintained hematocrit levels below 45% and reduced or eliminated the need for phlebotomy Safety […]
September is Blood Cancer Awareness Month for MPNs
by Lou Ann Donovan and David Wallace National Blood Cancer Awareness Month: Spotlight on Myeloproliferative Neoplasms September marks National Blood Cancer Awareness Month, an annual event established by Congress in 2010 to shed light on various blood diseases, including the lesser-known chronic blood cancers called Myeloproliferative Neoplasms (MPNs). The statistics are sobering: every three minutes, […]
What Are The Key Factors in Predicting Polycythemia Vera Progression?
by David Wallace A new study has shed light on the factors that may predict polycythemia vera (PV) disease progression. The REVEAL study, presented at the 2024 European Hematology Association Congress, has identified five key characteristics that could help doctors better understand which patients are at higher risk of their condition worsening over time. Polycythemia […]
Polycythemia Vera Exercise Recommendations
Abstract Background Exercise therapy during cancer treatment reduces symptom burden and improves quality of life (QoL). Polycythemia vera (PV) is a myeloproliferative neoplasia associated with good overall survival (up to decades) but a significant symptom burden, including thromboembolic events and dysesthesias. There are no specific exercise recommendations for patients with PV. Thus, we aimed to […]
